TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF GLOBAL VISCOSUPPLEMENTATION MARKET 24
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26
2 MARKET SEGMENTATION 29
2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 DBMR TRIPOD DATA VALIDATION MODEL 31
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.6 MULTIVARIATE MODELLING 35
2.7 MARKET APPLICATION COVERAGE GRID 36
2.8 SOURCE LIFELINE CURVE 37
2.9 DBMR MARKET POSITION GRID 38
2.10 VENDOR SHARE ANALYSIS 40
2.11 SECONDARY SOURCES 41
2.12 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHT 45
4.1 PESTEL 46
4.2 PORTER'S FIVE FORCES MODEL 47
5 EPIDEMIOLOGY 48
6 INDUSTRIAL INSIGHTS 49
7 EUROPE VISCOSUPPLEMENTATION MARKET: REGULATIONS 50
8 MARKET OVERVIEW 52
8.1 DRIVERS 54
8.1.1 RISING GERIATRIC POPULATION 54
8.1.2 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS 54
8.1.3 TECHNOLOGICAL ADVANCEMENT IN VISCOSUPPLEMENTATION 54
8.2 RESTRAINTS 55
8.2.1 LACK OF TECHNICAL EXPERTISE 55
8.2.2 PRODUCT RECALL PROCEDURES 55
8.2.3 LIMITED APPLICATIONS OF VISCOSUPPLEMENTATION 56
8.3 OPPORTUNITIES 56
8.3.1 SAFETY AND EFFECTIVENESS OF INTRA-ARTICULAR HYALURONIC ACID (IAHA) 56
8.3.2 RISING HEALTHCARE EXPENDITURE 56
8.3.3 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES 57
8.3.4 INCREASING NUMBER OF JOINT REPLACEMENTS AND SPORTS ACCIDENT 57
8.4 CHALLENGES 58
8.4.1 STRINGENT GOVERNMENT POLICIES FOR THE USE OF VISCOSUPPLEMENTATION 58
8.4.2 SIDE-EFFECTS OF VISCOSUPPLEMENTATION 58
9 EUROPE VISCOSUPPLEMENTATION MARKET, BY SOURCE 59
9.1 OVERVIEW 60
9.2 NON-ANIMAL ORIGIN 63
9.2.1 DUROLANE 64
9.2.2 EUFLEXXA 64
9.2.3 ORTHOVISC 64
9.2.4 MONOVISC 64
9.2.5 CINGAL 64
9.2.6 VISCOSEAL 64
9.2.7 OSTEONIL 64
9.2.8 OTHERS 64
9.3 ANIMAL ORIGIN 65
9.3.1 HYLAN G-F 20 66
9.3.2 SYNVIC ONE 66
9.3.3 SYNVISC 66
9.3.4 OTHERS 66
9.3.5 HYALURONANS 67
9.3.6 HYALGAN 67
9.3.7 OTHERS 67
10 EUROPE VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT 68
10.1 OVERVIEW 69
10.2 INTERMEDIATE MOLECULAR WEIGHT 72
10.2.1 DUROLANE 72
10.2.2 EUFLEXXA 72
10.2.3 ORTHOVISC 73
10.2.4 MONOVISC 73
10.2.5 VISCOSEAL 73
10.2.6 OSTEONIL 73
10.2.7 OTHERS 73
10.3 HIGH MOLECULAR WEIGHT 73
10.3.1 SYNVIC ONE 74
10.3.2 SYNVIC 74
10.3.3 OTHERS 74
10.4 LOW MOLECULAR WEIGHT 74
10.4.1 HYLAGAN 75
10.4.2 CINGAL 75
10.4.3 OTHERS 75
11 EUROPE VISCOSUPPLEMENTATION MARKET, BY INJECTION 76
11.1 OVERVIEW 77
11.2 SINGLE INJECTION 80
11.3 THREE INJECTION 80
11.4 FIVE INJECTION 81
12 EUROPE VISCOSUPPLEMENTATION MARKET, BY AGE GROUP 82
12.1 OVERVIEW 83
12.2 GERIATRIC 86
12.3 ADULTS 86
13 EUROPE VISCOSUPPLEMENTATION MARKET, BY END USER 87
13.1 OVERVIEW 88
13.2 HOSPITALS 91
13.3 ORTHOPEDIC CLINICS 91
13.4 AMBULATORY CARE CENTERS 92
13.5 OTHERS 92
14 EUROPE VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL 93
14.1 OVERVIEW 94
14.2 DIRECT TENDER 97
14.3 RETAIL SALES 97
15 EUROPE VISCOSUPPLEMENTATION MARKET, BY REGION 98
15.1 GERMANY 103
15.2 FRANCE 108
15.3 U.K. 113
15.4 ITALY 118
15.5 RUSSIA 123
15.6 SPAIN 128
15.7 TURKEY 133
15.8 NETHERLANDS 139
15.9 SWITZERLAND 144
15.10 POLAND 150
15.11 HUNGARY 156
15.12 AUSTRIA 162
15.13 NORWAY 167
15.14 IRELAND 172
15.15 LITHUANIA 177
15.16 REST OF EUROPE 183
16 EUROPE VISCOSUPPLEMENTATION MARKET: COMPANY LANDSCAPE 184
16.1 COMPANY SHARE ANALYSIS: EUROPE 184
17 COMPANY PROFILE 185
17.1 JOHNSON & JOHNSON SERVICES, INC. 185
17.1.1 COMPANY SNAPSHOT 185
17.1.2 REVENUE ANALYSIS 185
17.1.3 COMPANY SHARE ANALYSIS 186
17.1.4 PRODUCT PORTFOLIO 186
17.1.5 RECENT DEVELOPMENTS 186
17.2 SANOFI-AVENTIS U.S. LLC 187
17.2.1 COMPANY SNAPSHOT 187
17.2.2 REVENUE ANALYSIS 187
17.2.3 COMPANY SHARE ANALYSIS 188
17.2.4 PRODUCT PORTFOLIO 188
17.2.5 RECENT DEVELOPMENTS 188
17.3 FERRING B.V. 189
17.3.1 COMPANY SNAPSHOT 189
17.3.2 COMPANY SHARE ANALYSIS 189
17.3.3 PRODUCT PORTFOLIO 189
17.3.4 RECENT DEVELOPMENT 189
17.4 ZIMMER BIOMET 190
17.4.1 COMPANY SNAPSHOT 190
17.4.2 REVENUE ANALYSIS 190
17.4.3 COMPANY SHARE ANALYSIS 191
17.4.4 PRODUCT PORTFOLIO 191
17.4.5 RECENT DEVELOPMENTS 191
17.5 SEIKAGAKU CORPORATION 192
17.5.1 COMPANY SNAPSHOT 192
17.5.2 REVENUE ANALYSIS 192
17.5.3 PRODUCT PORTFOLIO 193
17.5.4 RECENT DEVELOPMENTS 193
17.6 ANIKA THERAPEUTICS, INC. 194
17.6.1 COMPANY SNAPSHOT 194
17.6.2 REVENUE ANALYSIS 194
17.6.3 PRODUCT PORTFOLIO 195
17.6.4 RECENT DEVELOPMENTS 195
17.7 APTISSEN 196
17.7.1 COMPANY SNAPSHOT 196
17.7.2 PRODUCT PORTFOLIO 196
17.7.3 RECENT DEVELOPMENT 196
17.8 BIOVENTUS 197
17.8.1 COMPANY SNAPSHOT 197
17.8.2 REVENUE ANALYSIS 197
17.8.3 COMPANY SHARE ANALYSIS 198
17.8.4 PRODUCT PORTFOLIO 198
17.8.5 RECENT DEVELOPMENTS 199
17.9 FIDIA FARMACEUTICI S.P.A 200
17.9.1 COMPANY SNAPSHOT 200
17.9.2 REVENUE ANALYSIS 200
17.9.3 PRODUCT PORTFOLIO 201
17.9.4 RECENT DEVELOPMENT 201
17.10 IBSA INSTITUT BIOCHIMIQUE SA 202
17.10.1 COMPANY SNAPSHOT 202
17.10.2 PRODUCT PORTFOLIO 202
17.10.3 RECENT DEVELOPMENT 202
17.11 LG CHEM. 203
17.11.1 COMPANY SNAPSHOT 203
17.11.2 REVENUE ANALYSIS 203
17.11.3 PRODUCT PORTFOLIO 204
17.11.4 RECENT DEVELOPMENTS 204
17.12 TEVA PHARMACEUTICAL INDUSTRIES LTD. 205
17.12.1 COMPANY SNAPSHOT 205
17.12.2 REVENUE ANALYSIS 205
17.12.3 PRODUCT PORTFOLIO 206
17.12.4 RECENT DEVELOPMENTS 206
17.13 TRB CHEMEDICA SA 207
17.13.1 COMPANY SNAPSHOT 207
17.13.2 PRODUCT PORTFOLIO 207
17.13.3 RECENT DEVELOPMENTS 207
17.14 VIATRIS INC. 209
17.14.1 COMPANY SNAPSHOT 209
17.14.2 REVENUE ANALYSIS 209
17.14.3 PRODUCT PORTFOLIO 210
17.14.4 RECENT DEVELOPMENTS 210
18 QUESTIONNAIRE 211
19 RELATED REPORTS 214

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.